News | March 10, 2026
Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
The first of four planned modules at the new plant is expected to come online by summer 2026
The first of four planned modules at the new plant is expected to come online by summer 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
The facility is expected to become operational by FY2028-29
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Nadda underlined that India’s policy framework is aligned with this transformation
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
Subscribe To Our Newsletter & Stay Updated
